

W96 EFFICACY OF 4/7DAYS MAINTENANCE ART STRATEGY: ANRS-170 QUATUOR TRIAL


Roland Landman

*Université de Paris, INSERM, IMEA, Hôpital Bichat-Claude Bernard, AP-HP, Paris,
France*

Disclosure: * Disclosures : Research grant from Viiv Healthcare, Inc., Gilead Science, Inc., Merck & Co, Inc

QUATUOR - Study design

randomized, multicenter, national, open-label, non-inferiority study in adults with HIV-1 virological suppression




Baseline Characteristics	Total 4/7 Days n=621
Age, year, median (IQR)	49 (41 – 55)
Male sex, n (%)	525 (84.5)
CD4 at screening (cells/mm ³), median (IQR)	692 (532 - 884)
Duration on ARV, year, median (IQR)	6.9 (4.0 – 12.4)
Duration of virological suppression (<50 c/mL), year, median (IQR)	5.8 (3.4 – 9.7)
Baseline NRTI , n (%)	
- TDF-TAF/FTC	452 (72.8)
- ABC/3TC	169 (27.2)
Baseline third agent class , n (%)	
- INI (DTG/EVG/RAL)	300 (48.3)
- NNRTI (RPV/EFV/ETR)	286 (46.1)
- PI (DRV/ATV/LPV)	35 (5.6)

OBJECTIVES :


- W48 : to establish non-inferiority of antiviral activity of 4D/7 versus 7D/7 with 5% non inferiority margin between groups
- W96 : long term follow-up efficacy and tolerance of 4D/7

ANRS 170 - QUATUOR STUDY - RESULTS

RANDOMISED PERIOD - W48



LONG TERM PERIOD- D0 to W96 (n=621) on 4D/7



(VF defined as 2 consecutive VL \geq 50 copies/mL)

Regarding the 3rd agent class, VF was observed in 5.3% [1.9-8.6] with NNRTI, and 2.4% [0.6-4.1] with InSTI at W96

QUATUOR - Virological failure and Tolerance: Week 96

Virological failure / New drug resistance mutations

Follow-up period	Virological failure	Patients with new DRM
D0-W48	6 /318	3 /6 : <ul style="list-style-type: none">- M184I, E138K, Y188L- M184V, E138K, V179I, H221Y- M184I, N155H
W48-W96	13/621	4/13 : <ul style="list-style-type: none">- M184I- E138K, M184V- M184I/M- K65K/R, E138K/E, V179I, K219E, F227F/C

Tolerance

- No significant adverse events, biological changes or changes in the level of pro-inflammatory markers were observed with the 4/7-days strategy until W96, except a gain of +4 ml/min (IQR -2;+6) in eGFR, p<0.001
- Strategy interruption for adverse event (n=3) and death (n=5 – 2 cancers, 1 domestic accident, 1 stroke, 1 myocardial infarction)

ANRS 170 - QUATUOR : Conclusions

Randomized period of follow-up at 48 weeks :

- The ANRS 170 QUATUOR randomized trial demonstrates the non-inferiority of a 4/7 days versus 7/7 days maintenance strategy whatever the 3rd agent class. Landman R. IAS 2019 abstract WEAB0406LB
- No change on HIV ADN/Ultra sensitive plasma viral load/ HIV seminal viral load between 4/7-days group relative to the 7/7-days. Lambert-Niclot S.CROI 2020 abstract 0502
- In the 4/7-days group, 152 participants (60.3%) reported an improvement in daily life satisfaction versus only 18 (7.3%) in the 7/7-days group ($P < 0.001$).
- Reduction of 43% of the cost of antiretroviral drug in the 4/7-days group relative to the 7/7-days group ($P < 0.001$).

Long term follow-up at 96week:

The efficacy result of 4/7-days strategy was sustained at W96, with a low rate of viral failure, particularly with InSTI based regimen.

This 4 consecutive days-on and 3 days-off reduced the cost ART maintenance regimens and represents a real, workable, alternative to the recommended maintenance therapy

ANRS 170 QUATUOR - Acknowledgments



We thank everyone who contributed to the success of this trial :

- All study participants
- The QUATUOR clinical investigators and their staff in France

PI : Dr. Roland Landman and Dr. Pierre de Truchis

Statistics : Lambert Assoumou, Jonathan Bellet, Dominique Costagliola

Coordination and monitoring IMEA: Karine Amat, Aïda Benalycherif, Babacar Sylla

**Virology coordination : Pr. Laurence Morand-Joubert, Dr. Sidonie Lambert
Pharmacology coordination : Pr. Jean-Claude Alvarez, Dr. Emuri Abe
Immunology coordination: S. Fellahi, Dr Pr. Jacqueline Capeau**

DSMB: Pr. Rodolphe Thiebaut, Pr Nathan Clumeck, Dr. Francesca Ceccherini-Silberstein , Dr. Laurent Decosterd, Vincent Leclercq

President scientific committee : Pr Pierre Marie Girard

**TRT-5 patients association: Vincent Leclerc, Marek Korzec
ICARRE association, Dr.Jacques Leibowitch**

Sponsor : ANRS-Inserm – Pr.François Dabis, Ventzislava Petrov-Sanchez, Ambre Gelley, Séverine Gibowski, Guillaume Le Meut

INVESTIGATORS :

I. Lamaury, F. Bani-Sadr, , G. Force, A. Chabrol, P. Genet, O. Patey, C. Drobacheff-Thiebaut- C. Chirouze, ,A. Fresard, C. Duvivier, V. Tolsma, N. Lerolle, A. Rami, G. Pichancourt, P. de Truchis, J. Bottero, G. Pialoux, O. Bouchaud, S. Abgrall, L. Weiss, D. Salmon-Céron, D. Zucman, J.D Lelièvre, C. Katlama, A. Simon, P.M. Girard, J.M. Molina, A. Cabié, P. Morlat, D. Neau, C. Genet, D. Makhloufi, I. Poizot-Martin, R. Landman, J. Reynes, F. Raffi, O. Bollengier-Stragier , A. Naqvi, E. Rosenthal, C. Arvieux, R. Buzelé, M.L. Batard, L. Bernard, P. Delobel, R. Verdon, L. Piroth, P. Leclercq, F. Ajana, M. André, P. Miaillhes, A. Greder, B. Elharrar, M.A. Khuong, L. Blum,P. Philibert, L. Slama, H. Hitoto, I. Darasteanu

